Bisphosphonates tied to lower breast cancer risk in meta-analysis

  • Liu Y & al.
  • Clin Epidemiol
  • 1 janv. 2019

  • Par Miriam Davis, PhD
  • Résumés d'articles
L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte. L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte.

Takeaway

  • A meta-analysis of 10 studies finds that bisphosphonates are associated with a 12% lower risk of breast cancer.
  • 2 of the studies, both randomized controlled trials (RCTs), found no relationship but were compromised by flaws in study design.

Why this matters

  • The authors call for a new RCT to resolve the discrepancy vs observational studies.

Study design

  • Meta-analysis of 10 studies (n>900,000) obtained from MEDLINE, EMBASE, Cochrane libraries, ProQuest, and Web of Science.
  • Study designs: 2 RCTs, 5 cohort studies, and 3 case-control studies.
  • Funding: None disclosed.

Key results

  • Bisphosphonate use was associated with 12% lower risk for primary breast cancer (risk reduction [RR], 0.88; 95% CI, 0.83-0.94).
    • Similar associations were found with cohort (RR, 0.83; 95% CI, 0.71-0.98) and case-control studies (RR, 0.87; 95% CI, 0.80-0.95).
    • 2 RCTs showed no association (RR, 1.127; 95% CI, 0.808-1.573), but were not designed to assess breast cancer outcomes (selective reporting bias).
  • Stratified analysis of the 10 studies showed that longer-term bisphosphonate use (≥1 year) had a greater effect on breast cancer risk reduction (RR, 0.75; 95% CI, 0.66-0.84) than short-term use (

Limitations

  • Heterogeneity across studies, including differences in bisphosphonate type.
  • Potential residual confounding.